N-of-One,
the leading provider of molecular interpretation and therapeutic
strategies for precision medicine for oncology, presented data
suggesting that up to 50% of BRAF gene mutations can be found in
locations other than the most common location, codon V600. In addition,
though BRAF is most common in melanoma, N-of-One reported on BRAF
mutations in others cancers as well, including lung, colorectal and
thyroid cancers. N-of-One presented the data in a poster presentation at
the Advances
in Genome Biology and Technology (AGBT) meeting, held February
12-15, 2014 in Marco Island, Florida.

The findings were derived from a dataset of over 4,000 sequenced tumors
N-of-One has interpreted, including 164 tumors cotaining BRAF
alterations.

"These findings suggest that additional research to characterize BRAF
mutations, both on codon V600 and other locations we've highlighted,
could benefit many patients, not only those with melanoma but also those
with other cancers that include BRAF mutations," said Dr. Jennifer Levin
Carter, Chief Medical Officer of N-of-One. "In addition to
standard-of-care therapy targeting V600, there is evidence that some of
these additional mutations may be amenable to targeted therapy,
specifically therapeutic approaches that may include MEK inhibitors and
CRAF inhibitors (sorafenib). Using next-generation sequencing to explore
the entire coding region of BRAF, in a variety of tumor types, will
expand treatment options for patients and lead to the identification of
more potentially targetable mutations."

About N-of-One

N-of-One,
a leader in precision medicine for oncology, leverages its world-class
team of experts to translate molecular data specific to each patient
into state-of-the-art, clinical
insights and therapeutic options. N-of-One's team of experts has
interpreted more than 6,000 tumors for oncologists and patients
worldwide, through partnerships to provide clinical interpretation for
leading diagnostic companies (such as Foundation Medicine and Clarient),
through agreements with provider networks (such as Fox Chase Cancer
Center in Philadelphia), directly to oncologists and through employee
access benefit programs (such as Life Technologies). N-of-One does not
provide medical advice or promote any product or service. For more
information, please visit www.n-of-one.com
or call 617-202-9808.